tradingkey.logo

AstraZeneca PLC

AZN

77.475USD

-0.485-0.62%
交易中 03/06, 11:03美东报价延迟15分钟
240.25B总市值
34.15市盈率 TTM

AstraZeneca PLC

77.475

-0.485-0.62%
关于 AstraZeneca PLC 公司
公司简介
公司代码AZN
公司名称AstraZeneca PLC
上市日期Sep 21, 2007
成立日期1992
CEOMr. Marc Dunoyer
员工数量94300
证券类型Ordinary Share
年结日Sep 21
公司地址1 Francis Crick Avenue
城市CAMBRIDGE
上市交易所London Stock Exchange
国家United Kingdom
邮编CB2 0AA
电话442073045000
网址https://www.astrazeneca.com/
公司代码AZN
上市日期Sep 21, 2007
成立日期1992
公司高管
名称
名称/职务
职务
持股
持股变动
Ms. Susan Galbraith
Ms. Susan Galbraith
Executive Vice President - Oncology and Research and Development
Executive Vice President - Oncology and Research and Development
--
--
Mr. Marc Dunoyer
Mr. Marc Dunoyer
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
--
--
Mr. David (Dave) Fredrickson
Mr. David (Dave) Fredrickson
Executive Vice President - Oncology Business Unit
Executive Vice President - Oncology Business Unit
--
--
Mr. Pascal Soriot
Mr. Pascal Soriot
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Philip Broadley
Mr. Philip Broadley
Senior Non-Executive Independent Director
Senior Non-Executive Independent Director
--
--
Dr. Ruud Dobber, Ph.D.
Dr. Ruud Dobber, Ph.D.
Executive Vice President - BioPharmaceuticals Business Unit
Executive Vice President - BioPharmaceuticals Business Unit
--
--
Ms. Deborah Disanzo Eldracher
Ms. Deborah Disanzo Eldracher
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Diana Layfield
Ms. Diana Layfield
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Rene Haas
Mr. Rene Haas
Non-Executive Director
Non-Executive Director
--
--
Mr. Michel Demare
Mr. Michel Demare
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Ms. Susan Galbraith
Ms. Susan Galbraith
Executive Vice President - Oncology and Research and Development
Executive Vice President - Oncology and Research and Development
--
--
Mr. Marc Dunoyer
Mr. Marc Dunoyer
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
--
--
Mr. David (Dave) Fredrickson
Mr. David (Dave) Fredrickson
Executive Vice President - Oncology Business Unit
Executive Vice President - Oncology Business Unit
--
--
Mr. Pascal Soriot
Mr. Pascal Soriot
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Philip Broadley
Mr. Philip Broadley
Senior Non-Executive Independent Director
Senior Non-Executive Independent Director
--
--
Dr. Ruud Dobber, Ph.D.
Dr. Ruud Dobber, Ph.D.
Executive Vice President - BioPharmaceuticals Business Unit
Executive Vice President - BioPharmaceuticals Business Unit
--
--
收入明细
单位: USD更新时间: 3月5日 周三
单位: USD更新时间: 3月5日 周三
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Farxiga
7.65B
15.03%
Tagrisso
6.58B
12.91%
Imfinzi
4.71B
9.26%
Ultomiris
3.92B
7.70%
Calquenc
3.12B
6.14%
Other
24.93B
48.94%
地区USD
名称
营收
占比
United States
21.80B
42.80%
China
6.41B
12.60%
United Kingdom
4.74B
9.30%
Other European Countries
3.66B
7.19%
Japan
3.45B
6.77%
Other
10.85B
21.31%
业务
地区
业务USD
名称
营收
占比
Farxiga
7.65B
15.03%
Tagrisso
6.58B
12.91%
Imfinzi
4.71B
9.26%
Ultomiris
3.92B
7.70%
Calquenc
3.12B
6.14%
Other
24.93B
48.94%
股东统计
更新时间: 2月21日 周五
更新时间: 2月21日 周五
持股股东
股东类型
持股股东
股东统计
占比
PRIMECAP Management Company
1.32%
Capital International Investors
1.20%
Wellington Management Company, LLP
1.19%
T. Rowe Price Associates, Inc.
1.08%
T. Rowe Price International Ltd
0.85%
Other
94.32%
持股股东
股东统计
占比
PRIMECAP Management Company
1.32%
Capital International Investors
1.20%
Wellington Management Company, LLP
1.19%
T. Rowe Price Associates, Inc.
1.08%
T. Rowe Price International Ltd
0.85%
Other
94.32%
股东类型
股东统计
占比
Investment Advisor
9.43%
Investment Advisor/Hedge Fund
6.01%
Hedge Fund
0.96%
Research Firm
0.88%
Bank and Trust
0.14%
Holding Company
0.07%
Pension Fund
0.04%
Venture Capital
0.02%
Family Office
0.01%
Other
82.39%
机构持股
更新时间: 1月19日 周日
更新时间: 1月19日 周日
报告期
机构数
持股数
持股占比
持股变动
2025Q1
1935
545.66M
17.59%
+11.80M
2024Q4
1985
546.16M
17.61%
+11.21M
2024Q3
1920
519.94M
16.76%
-17.36M
2024Q2
1910
530.79M
17.12%
-10.50M
2024Q1
1865
523.00M
16.86%
-21.20M
2023Q4
1838
520.78M
16.79%
-27.27M
2023Q3
1815
530.16M
17.10%
-14.80M
2023Q2
1812
525.35M
16.94%
-28.73M
2023Q1
1803
534.30M
17.23%
-35.06M
2022Q4
1806
550.26M
17.75%
-33.14M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
PRIMECAP Management Company
41.01M
1.32%
-960.51K
-2.28%
Dec 31, 2024
Capital International Investors
37.50M
1.2%
+686.00K
+1.86%
Dec 31, 2024
Wellington Management Company, LLP
37.03M
1.19%
-208.19K
-0.55%
Dec 31, 2024
T. Rowe Price Associates, Inc.
33.74M
1.08%
-3.07M
-8.34%
Dec 31, 2024
T. Rowe Price International Ltd
26.60M
0.85%
+530.21K
+2.03%
Dec 31, 2024
Fidelity Management & Research Company LLC
18.14M
0.58%
-1.09M
-5.70%
Dec 31, 2024
Managed Account Advisors LLC
15.80M
0.5%
+7.65M
+93.93%
Dec 31, 2024
Jennison Associates LLC
15.43M
0.49%
+466.41K
+3.11%
Dec 31, 2024
Sanders Capital, LLC
15.18M
0.48%
+212.30K
+1.41%
Dec 31, 2024
Invesco Capital Management (QQQ Trust)
11.80M
0.38%
+233.78K
+2.01%
Dec 31, 2024
查看更多
持股ETF
更新时间: 16 小时前
更新时间: 16 小时前
机构名称
占比
First Trust WCM International Equity ETF
5.11%
VanEck Pharmaceutical ETF
4.9%
Amplify Weight Loss Drug & Treatment ETF
4.51%
Roundhill GLP-1 & Weight Loss ETF
4.38%
ProShares Ultra Nasdaq Biotechnology
4.04%
Invesco Nasdaq Biotechnology ETF
3.82%
PGIM Jennison Focused Value ETF
3.4%
Franklin Genomic Advancements ETF
2.9%
Global X Aging Population ETF
2.77%
Amplify International Enhanced Dividend Income ETF
2.33%
查看更多
First Trust WCM International Equity ETF
占比5.11%
VanEck Pharmaceutical ETF
占比4.9%
Amplify Weight Loss Drug & Treatment ETF
占比4.51%
Roundhill GLP-1 & Weight Loss ETF
占比4.38%
ProShares Ultra Nasdaq Biotechnology
占比4.04%
Invesco Nasdaq Biotechnology ETF
占比3.82%
PGIM Jennison Focused Value ETF
占比3.4%
Franklin Genomic Advancements ETF
占比2.9%
Global X Aging Population ETF
占比2.77%
Amplify International Enhanced Dividend Income ETF
占比2.33%
分红派息
近5年累计派现 20.90B 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
Feb 06, 2025
AZN.NB Interim Cash Dividend of gross USD 1.05 paid on Mar 24, 2025 going ex on Feb 21, 2025
Feb 21, 2025
Mar 24, 2025
Feb 21, 2025
Jul 25, 2024
AZN.NB Final Cash Dividend of gross USD 0.5 paid on Sep 09, 2024 going ex on Aug 09, 2024
Aug 09, 2024
Sep 09, 2024
Aug 09, 2024
Feb 08, 2024
AZN.NB Interim Cash Dividend of gross USD 0.985 paid on Mar 25, 2024 going ex on Feb 22, 2024
Feb 23, 2024
Mar 25, 2024
Feb 22, 2024
Jul 28, 2023
AZN.NB Final Cash Dividend of gross USD 0.465 paid on Sep 11, 2023 going ex on Aug 10, 2023
Aug 11, 2023
Sep 11, 2023
Aug 10, 2023
Feb 10, 2023
AZN.NB Interim Cash Dividend of gross USD 0.985 paid on Mar 27, 2023 going ex on Feb 23, 2023
Feb 24, 2023
Mar 27, 2023
Feb 23, 2023
Aug 01, 2022
AZN.NB Final Cash Dividend of gross USD 0.465 paid on Sep 12, 2022 going ex on Aug 11, 2022
Aug 12, 2022
Sep 12, 2022
Aug 11, 2022
Feb 10, 2022
AZN.NB Interim Cash Dividend of gross USD 0.985 paid on Mar 28, 2022 going ex on Feb 24, 2022
Feb 25, 2022
Mar 28, 2022
Feb 24, 2022
Aug 02, 2021
AZN.NB Final Cash Dividend of gross USD 0.45 paid on Sep 13, 2021 going ex on Aug 12, 2021
Aug 13, 2021
Sep 13, 2021
Aug 12, 2021
Feb 11, 2021
AZN.NB Interim Cash Dividend of gross USD 0.95 paid on Mar 29, 2021 going ex on Feb 25, 2021
Feb 26, 2021
Mar 29, 2021
Feb 25, 2021
Jul 30, 2020
AZN.NB Final Cash Dividend of gross USD 0.45 paid on Sep 14, 2020 going ex on Aug 13, 2020
Aug 14, 2020
Sep 14, 2020
Aug 13, 2020
查看更多
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
tradingkey.logo
tradingkey.logo
日内数据由路孚特(Refinitiv)提供,并受使用条款约束。历史及当前收盘数据均由路孚特提供。所有报价均以当地交易所时间为准。美股报价的实时最后成交数据仅反映通过纳斯达克报告的交易。日内数据延迟至少15分钟或遵循交易所要求。
* 参考、分析和交易策略由第三方提供商Trading Central提供,观点基于分析师的独立评估和判断,未考虑投资者的投资目标和财务状况。
风险提示:我们的网站和移动应用程序仅提供关于某些投资产品的一般信息。Finsights 不提供财务建议或对任何投资产品的推荐,且提供此类信息不应被解释为 Finsights 提供财务建议或推荐。
投资产品存在重大投资风险,包括可能损失投资的本金,且可能并不适合所有人。投资产品的过去表现并不代表其未来表现。
Finsights 可能允许第三方广告商或关联公司在我们的网站或移动应用程序的任何部分放置或投放广告,并可能根据您与广告的互动情况获得报酬。
© 版权所有: FINSIGHTS MEDIA PTE. LTD. 版权所有